Inhibikase Therapeutics, Inc. today announced that the first patient has been dosed in its Phase 2 ‘201’ trial evaluating IkT-148009, the Company’s novel Abelson Tyrosine Kinase, or c-Abl, inhibitor for the treatment of Parkinson’s disease.
Soligenix, Inc. announced today that the European Patent Office has granted a patent entitled “Novel Peptides and Analogs for Use in the Treatment of Oral Mucositis”.
Soligenix Announces European Patent Grant for Use of Dusquetide in Oral Mucositis Read More »
Aviceda Therapeutics today announced the appointment of Patrick Johnson to its board of directors.
BD (Becton, Dickinson and Company) today announced 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the new BD Kiestra™ Methicillin-resistant Staphylococcus aureus (MRSA) imaging application that uses artificial intelligence (AI) to interpret bacterial growth and release negative specimens with minimal human interaction.
BD Gains 510(k) Clearance of Artificial Intelligence Software for MRSA Diagnostics Read More »
NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced its financial results for the first quarter of 2023 and provided a business update.
NanoViricides, Inc., reports that it has filed its Quarterly Report on Form 10-Q for the fiscal third quarter ending March 31, 2023 with the Securities and Exchange Commission on Monday, May 15, 2023.
Caris Life Sciences® announced that Robert H. Lurie Comprehensive Cancer Center of Northwestern University has joined the Caris Precision Oncology Alliance™.
Bioretec Ltd, a pioneer in bioresorbable orthopedic implants, announces that Dr. Jeremy Dublon joins the Bioretec team to support Company’s U.S. commercialization strategy from a clinical and regulatory perspective.
Former U.S. White House Surgeon and FDA Medical Officer joins Bioretec team Read More »
Beactica Therapeutics AB, the Swedish precision oncology company, announced that its YAP-TEAD programme has been selected for an oral presentation at the 2nd Hippo Pathway Targeted Drug Development Summit 2023.
RadioMedix and Orano Med, two clinical stage radiopharmaceutical companies, announced that the last patient has been dosed in the Phase II trial of the targeted alpha emitter therapy, 212Pb-DOTAMTATE.
